STOCK TITAN

ACURA PHARMS INC - $ACUR STOCK NEWS

Welcome to our dedicated page for ACURA PHARMS news (Ticker: $ACUR), a resource for investors and traders seeking the latest updates and insights on ACURA PHARMS stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect ACURA PHARMS's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of ACURA PHARMS's position in the market.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.84%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.53%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-12.17%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.61%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
35.6%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
ACURA PHARMS INC

OTC:ACUR

ACUR Rankings

ACUR Stock Data

184.81k
9.94M
84.73%
2.96%
0.76%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
Palatine

About ACUR

acura pharmaceuticals, inc. is a specialty pharmaceutical company engaged in the research, development and commercialization of technologies and products intended to address medication abuse and misuse. we have discovered and developed three proprietary technology platforms to address abuse and misuse across multiple fronts. • limitx™ technology is designed to retard the release of active drug ingredients when an excess number of tablets are ingested. in 2014, we were awarded a $300,000 grant from the national institute on drug abuse to advance early stage development of our limitx technology. • aversion® technology is a patented composition of commonly used active and inactive pharmaceutical ingredients providing abuse deterrent features to discourage common methods of pharmaceutical product misuse and abuse while providing effective pain relief. oxaydo® tablets (oxycodone hcl, cii), is the first approved product using aversion® in the united states. on january 7, 2015, we entered int